Table 1.
Demographic and biomedical information on study participants.
| Variable | N | Hospital (n=70) |
Institution (n=10) |
All patients | P b | |
| Age (years) | 79 |
|
|
|
.58 | |
|
|
Mean (SD) |
|
46.9 (11.2) | 44.4 (8.9) | 46.7 (10.9) |
|
|
|
IQR |
|
39.5-53.0 | 37.0-51.0 | 39.0-53.0 |
|
| Gender, n (%) | 79 |
|
|
|
.12 | |
|
|
Male |
|
44 (63) | 8 (89) | 52 (66) |
|
|
|
Female |
|
26 (37) | 1 (11) | 27 (34) |
|
| Not currently working | 78 | 15 (21) | 6 (75) | 21 (27) | .005 | |
| Education level (university), n (%) | 78 | 29 (41) | 4 (50) | 33 (42) | .93 | |
| Marital status (single), n (%) | 77 | 33 (48) | 5 (62) | 38 (49) | .68 | |
| Living alone, n (%) | 78 | 31 (44) | 8 (100) | 39 (50) | .009 | |
| Comorbidities, n (%) |
|
|
|
|
|
|
|
|
Depression | 78 | 9 (13) | 3 (38) | 12 (15) | .07 |
|
|
Psychiatric disorder | 78 | 1 (1) | 0 (0) | 1 (1) | .73 |
|
|
Cardiovascular disease | 78 | 9 (13) | 3 (38) | 12 (15) | .07 |
|
|
Diabetes | 78 | 6 (9) | 1 (12) | 7 (9) | .71 |
|
|
Other comorbidities | 78 | 5 (7) | 0 (0) | 5 (6) | .43 |
|
|
Lipodystrophy | 79 | 15 (21) | 2 (22) | 17 (22) | .96 |
| Current treatment, n (%) | 78 |
|
|
|
|
|
|
|
Prophylaxisc |
|
3 (4) | 3 (38) | 6 (8) | <.001 |
|
|
Antidepressant |
|
8 (11) | 3 (38) | 11 (14) | .045 |
|
|
Lipid-lowering |
|
7 (10) | 0 (0) | 7 (9) | .35 |
| Year of diagnosis | 78 |
|
|
|
.19 | |
|
|
Mean (SD) |
|
1998 (8) | 2002 (7) | 1999 (8) |
|
|
|
IQR |
|
1990-2005 | 2000-2008 | 1991-2006 |
|
| HAART status, n (%) | 79 | 61 (87) | 9 (90) | 70 (89) | .99 | |
| CDC stage, n (%) | 79 |
|
|
|
|
|
|
|
A (asymptomatic) |
|
41 (59) | 2 (22) | 43 (54) | .07 |
|
|
B (symptomatic conditions) |
|
13 (19) | 2 (22) | 15 (19) |
|
|
|
C (AIDS-indicator conditions) |
|
16 (23) | 5 (56) | 21 (27) |
|
| Year of first HAART | 66 |
|
|
|
.02 | |
|
|
Mean (SD) |
|
2002 (6) | 2008 (3) | 2003 (6) |
|
|
|
IQR |
|
1996-2007 | 2007-2009 | 1997-2007 |
|
| Viral co-infection, n (%) |
|
|
|
|
|
|
|
|
Hepatitis C | 79 | 14 (20) | 0 (0) | 14 (18) | .31 |
|
|
Hepatitis B | 79 | 4 (6) | 1 (10) | 5 (6) | .99 |
| CD4 |
|
|
|
|
|
|
|
|
CD4 counts (cells/mm3), mean (SD) | 79 | 623 (438) | 407 (191) | 598 (422) | .04 |
|
|
IQR |
|
441-700 | 213-527 | 424-694 |
|
|
|
CD4 %, mean (SD) | 74 | 30.3 (10.2) | 20.2 (9.8) | 29.6 (10.4) | — |
|
|
IQR |
|
24-37 | 19-24 | 23-37 |
|
| Viral load (undetectable) | 21 | 1 (8) | 8 (89) | 9 (43) | .001 | |
aHAART: highly active antiretroviral therapy; CD4: cluster of differentiation 4, T helper cells playing a major role in the human immune system; CDC: Centers for Disease Control and Prevention (classification system for HIV-infected adults and adolescents).
bWilcoxon-Mann-Whitney test for 2 independent samples and Pearson chi-square.
cToxoplasmosis, pneumocystis.